6 results about "Oligodendroglia Cell" patented technology

Disclosed is a protein comprising no more than three human autoantigenic proteins, wherein a first human autoantigenic protein comprises a truncated myelin oligodendrocyte glycoprotein (MOG) amino acid sequence, a second human autoantigenic protein comprises a myelin basic protein (MBP) amino acid sequence, and a third human autoantigenic protein comprises a truncated proteolipid protein (PLP) amino acid sequence. Also disclosed are related nucleic acids, pharmaceutical compositions, methods of treating a demyelinating disease, and methods of producing the proteins.

The present application relates to the technical field of gene detection, in particular to a gene panel, method, device and use for somatic cell variation detection of SLC35A2 gene. The present application provides a gene panel, which can target capture the entire SLC35A2 gene related region, including exons, introns, promoters and enhancers, and carry out somatic cell variation detection, including SNVs, small Indels and SVs. The panel is used for detection of refractory epilepsy surgical brain tissue specimens, and can genetically diagnose mild cortical dysplasia with oligodendrogliosis epilepsy (MOGHE). This kind of disease is a new subtype of focal cortical dysplasia newly included by the International League Against Epilepsy in 2022. The panel has high variation detection rate and more comprehensive variation detection types.

A method of differentiating nonhuman primate induced pluripotent stem cells (iPSCs) to oligodendrocytes is provided. The method may include providing a modified vector comprising a piggyBac vector backbone that expresses one or more differentiation factor genes, including SOX10, OLIG2, and NKX6-2. The piggyBac vector backbone may comprise one or more terminal inverted repeats and one or more transposase recognition sites configured to interact with a piggyBac transposase to mediate genomic integration at TTAA or noncanonical target sequences. The vector may further include a selectable marker and a promoter for regulated expression. The modified vector may be introduced into nonhuman primate iPSCs, for example from Macaca fascicularis, by electroporation and used in a feeder-free differentiation workflow. The resulting differentiated cells may be identified by expression of oligodendrocyte-associated markers including O4, O1, PDGFRA, MOG, GALC, CNPase, and myelin basic protein (MBP).

A method of generating human mature oligodendrocytes is disclosed. The method comprises contacting a cell population which comprises human pre-oligodendrocytes with an inhibitor of the MAPK / ERK pathway under conditions that allow the pre-oligodendrocytes to differentiate into mature oligodendrocytes. Use of the MAPK / ERK pathway inhibitor for treating diseases is also disclosed.

The present application relates to nerve growth factor inducible protein or its gene in the preparation of treating spinal cord injury drug application. The present application proves that the lentivirus of overexpressing nerve growth factor inducible protein gene can promote the regeneration of oligodendrocytes, and then can effectively improve the recovery of motor function of spinal cord injury animal model through cell experiment and animal experiment.

Provided herein is a differentiation agent that consists essentially of SOX9 for the production of oligodendrocyte progenitor cells (OPCs) from pluripotent stem cells (PSCs). Also provided herein are methods of producing the PSCs and methods of using the PSCs to produce OPCs and oligodendrocytes.